The annual Molecular Targets and Cancer Therapeutics meeting returns to Boston later this week and from the program and abstracts we’ve reviewed it looks like it will be an exciting meeting that will offer insights into many new cancer drugs in development.
Sally Church, PhD describes it as her favourite cancer meeting of the year. It’s a must attend for anyone in oncology new product development.
Jointly organized by AACR-EORTC-NCI, like the Ryder Cup it alternates between America and Europe. According to an AACR press release:
“The meeting, focusing on cancer drug development, draws nearly 3,000 attendees and gathers academics, scientists, and representatives from the pharmaceutical industry to discuss the effects new discoveries in cancer therapeutics and target selection have in molecular biology.”
You can read more coverage of the meeting on Biotech Strategy Blog.